RecruitingAsthma
Study of CM512 Injection in Subjects With Moderate-to-severe Asthma
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.
Sponsor: Keymed Biosciences Co.Ltd
You may qualify if…
- ✓ Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form.
- ✓ Age ≥ 18 years old and ≤ 75 years old.
- ✓ Body mass index (BMI) ≥ 18.0 kg/(m\*m).
- ✓ Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1.
- ✓ Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.
- ✓ Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5
You may not qualify if…
- ✕ Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating.
- ✕ With a history of drug abuse within the past 5 years before screening visit.
- ✕ Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock.
- ✕ With any medical or non-medical conditions that are not suitable for participation in this study by investigators.
Source: ClinicalTrials.gov · NCT07011524 · last updated 2025-08-28